Why Zoetis (ZTS) Remains a Reliable Choice for Investors Seeking Profitable Dividend Stocks

Zoetis Inc. (NYSE:ZTS) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now.

Zoetis Inc. (NYSE:ZTS) offers a range of drugs and healthcare products for companion animals and livestock worldwide. The company keeps innovating with a portfolio that includes seven main product categories and about 300 product lines.

As younger generations show more interest in pets and the growing global population increases the need for animal proteins, the animal health market is set to expand. Zoetis Inc. (NYSE:ZTS)’s management predicts it will rise from $48 billion in 2023 to between $75 billion and $85 billion by 2033. Historically, the company has grown faster than the industry. Consumer priorities are shifting towards wellness and personalized medicine for pets. This trend drives growth in areas like nutrition, supplements, and therapies, which is promising for Zoetis’ leading pet business.

With 14 consecutive years of dividend growth, Zoetis Inc. (NYSE:ZTS) has always grabbed the attention of income investors. Currently, it offers a quarterly dividend of $0.50 per share for a dividend yield of 1.38%, as of October 6.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best BDC Stocks to Buy Now and Dividend Champions List: Top 15 Stocks to Buy.

Disclosure: None.